ASCO20: hydroxychloroquine and azithromycin combination treatment linked to greater mortality in cancer patients with COVID-19

Written by Caitlin Killen, Future Science group

Research due to be presented at the American Society of Clinical Oncology (ASCO) Virtual Meeting (29–31 May 2020) suggests that cancer progression in COVID-19 patients is associated with a greater death risk. The findings also report that the combination of hydroxychloroquine and azithromycin – a potential treatment option for COVID-19 – is also associated with an increased risk of death. The data was obtained from the COVID-19 and Cancer Consortium (CCC19) registry. The registry collects reports of cancer patients who have been diagnosed with COVID-19, it includes data reported by healthcare providers from the United States, Canada, Argentina, the European...

To view this content, please register now for access

It's completely free